Nanoscale technology is widely used in medicine where manipulations are made at the molecular level, taking advantage of the novel properties of a material. The primary demand of this field in medicine is in making improvements in the delivery of treatments and healthcare outcomes. Nanotechnology Drug Delivery refers to the usage of nanoscale healthcare materials and technology in pharmaceutical drug delivery to improve the efficacy of the drug.
Increasing the prevalence of chronic diseases and illnesses like cancer and cardiovascular diseases have increased the demand for novel drugs that have targeted delivery and are also more effective than traditional drugs. This factor has created the demand for a nanotechnology drug delivery system. Moreover, increasing advancements in nanoscale technologies and growing preference for personalized medicines have also helped the growth of the market.
However, the cost of nanotechnology drug delivery medicine and stringent regulations for the mechanism approval have restrained the growth of the market.
Scope of the Report
Nanotechnology drug delivery applications occur through the use of designed nanomaterials as well as forming delivery systems from nanoscale molecules. These materials help in improving the bioavailability of the drug. Nanotechnology drug delivery is widely used in the health care industry in applications such as neurology, anti-infective, cardiovascular disorders, and others.
In the report, a detailed analysis of the Nanotechnology drug delivery market is provided. The market is evaluated by collating revenues generated across segments, categorized by technology, application, and geography.
Key Market Trends
Application in Cardiovascular Segment is Expected to Cover a Large Market Share
Cardiovascular Diseases (CVD) are the leading cause of death globally. According to estimates by the World Health Organization, an estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Moreover, some other reports have also reported that the prevalence and number of deaths due to CVDs have increased and are expected to increase in the future as well.
According to the American Heart Association, the deaths per year are estimated to grow to more than 23.6 million by 2030. The increasing number of deaths will lead to increased burden among the people, which will increase the demand for novel nanotechnology drug delivery techniques that are efficient than traditional medicine and hence this is expected to drive the overall market to grow.
North America is Expected to Dominate the Nanotechnology Drug Delivery Market
North American countries have a high prevalence of cardiovascular diseases (CVD) and cancer. According to the National Cancer Institute, in 2018, an estimated 1.73 million new cases of cancer will be diagnosed in the United States and more than 600,000 people died from the disease.
According to World Health Organization data reported in 2018, nearly 24% of all the deaths in 2016 in Mexico were attributed to CVD, making it the leading cause of death in Mexico. Cardiovascular disease (CVD), listed as the underlying cause of death, accounted for 840,678 deaths in the US in 2016, as per the American Heart Association 2018 data. These high prevalence have increased the demand for novel nanotechnology drug delivery technology.
The increasing number of companies are found investing in research and development in this field are allowing for a rise in R&D activities, helping the market expand at a steady pace. There are also collaborations among leading pharmaceutical companies and technology developers that has picked pace in the market in the past few years. A number of companies are also focusing on the development of nanomedicines for the treatment of a variety of cancers.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases
4.2.2 Increasing Advancements in Nanoscale Technologies
4.2.3 Growing Preference for Personalized Medicines
4.3 Market Restraints
4.3.1 High Cost of Nanotechnology Drug Delivery Technique
4.3.2 Stringent Regulations for Commercial Introduction
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.2 By Application
5.2.6 Other Applications
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
5.3.3 Asia Pacific
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc
6.1.2 Aquanova AG
6.1.3 BlueWillow Biologics
6.1.4 Celgene Inc
6.1.5 CYTIMMUNE SCIENCES INC
6.1.7 NanoCarrier Co Ltd
6.1.8 NanOlogy LLC
6.1.9 Taiwan Liposome Co
6.1.10 Tarveda Therapeutics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.